Pertussis upsurge, age shift and vaccine escape post-COVID-19 caused by ptxP3 macrolide-resistant Bordetella pertussis MT28 clone in China: a genomic epidemiology study

Evidence before this study In the first two months of 2024, an unexpected upsurge in pertussis was seen in both China and Europe. Furthermore, the pertussis upsurge in China exhibited atypical patterns, including an age shift to older children, vaccine escape and a notable increase in macrolide-resistant Bordetella pertussis (MRBP) prevalence. We aimed to test the hypothesis linking pertussis upsurge and epidemiological transition to pathogen evolution. We searched PubMed for molecular epidemiology studies of macrolide-resistant Bordetella pertussis using the terms ("Bordetella pertussis" OR "pertussis” OR “whooping cough”) AND ("macrolide resistant" OR "erythromycin resistant”) for articles before March 2024 and identified 40 studies. MRBP has been reported in eight counties, including United States, United Kingdom, France, Iran, Cambodia, Vietnam, Japan and China. While MRBP incidence in other countries remained low, it was notably high in China, accounting for 50% and even 90% of strains across various regions. The risk of MRBP spreading out of China was previously considered low, primarily because Chinese strains predominantly belonged to ptxP1-lineage, whereas the globally prevalent lineage was ptxP3. However, the situation is changing, as ptxP3-MRBP strains have been identified in multiple regions of China since 2017. In Shanghai, we identified a sharply increase of ptxP3-MRBP prevalence post-COVID-19, coinciding with pertussis age shift to older children and vaccine escape. A similar scenario was independently observed in Beijing. Additionanlly, there is a significant rise in pertussis cases since the beginning of 2024. Currently, there is a lack of study testing the link between pertussis upsurge, epidemiological transition, and the evolution of its causative pathogen.

Added value of this study Our study identified a ptxP3-linage, macrolide-resistant novel clone, MR-MT28, which is uniquely capable of causing substantial infections among older children and vaccinated population, suggesting enhanced vaccine escape. The emergence and rapid expansion of MR-MT28 temporally strongly associated with the upsurge of pertussis cases, age shift, vaccine escape and notable rise in MRBP prevalence. MR-MT28 was characterized by increased expression of antigen genes long with high incidence of abnormal C-reactive protein, but associated with siginicantly milder clinical sytmptoms, which may prolong the interval before seeking medical care, thereby amplifying transmission opportunities. Phylogenomic clustering analysis indicated that MR-MT28 may have increased transmissibility. Therefore, MR-MT28 may have competitive advantages due to antimicrobial resistance, enhanced vaccine escape, increased opportunities for transmission and transmissibility. We reconstructed the evolutionary history of MR-MT28 and showed that it most likely originated in China around 2016 after the acquisition of several mutations, and COVID-19 may have promoted its expansion. Approximately one quarter of MR-MT28 strains has evolved into predicted PRN-deficient strains. Our results showed the domestic spread and colonization of MR-MT28.

Implications of all the available evidence Our study provides evidence that pathogen evolution, rather than the widely accepted notion of wanning immunity or ‘immunity debt’, is more likely the primary factor driving pertussis upsurge, age shift and vaccine escape. MR-MT28 potentially poses a high global spread risk, due to its consistent ptxP3 allele and epidemiology across many counties, together with resistance to first-line drugs and potentially competitive advantages, which warrants global surveillance and research efforts. Macrolides may no longer be suitable as first-line drugs for pertussis treatment in China.